Drug Trial Radar · NCT02120950
Aflibercept in Polypoidal Choroidal Vasculopathy
Last checked: Nov 20, 2026Latest source record: Dec 2, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
333
Actual
Start
May 29, 2014
Primary completion
Aug 12, 2016
Study completion Jul 7, 2017
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- Collaborators
- Regeneron Pharmaceuticals
- First posted
- Apr 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To collect data reflecting the efficacy and safety of aflibercept with and without photodynamic therapy in subjects diagnosed with the polypoidal choroidal vasculopathy subtype of wet age-related macular degeneration
Conditions
- Neovascular Macular Degeneration
Interventions
Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)Drug
Eylea is administered as an intravitreal injection
VisudyneOther
Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment of Diabetic Retinopathy Study (ETDRS) Letter Scores From Baseline to Week 52 - Last Observation Carried Forward (LOCF)Time frame: From Baseline to Week 52
Locations
62 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Parramatta, Australia
Site not named
Liverpool, New South Wales, Australia
Site not named
Strathfield, New South Wales, Australia
Site not named
Westmead, New South Wales, Australia
Site not named
East Melbourne, Victoria, Australia
Site not named
München, Germany
Site not named
Hong Kong, Hong Kong
Site not named
Kowloon, Hong Kong
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Budapest, Hungary
Site not named
Debrecen, Hungary
Site not named
Akita, Japan
Site not named
Aomori, Japan
Site not named
Chiba, Japan
Site not named
Fukuoka, Japan
Site not named
Fukuoka, Japan
Site not named
Fukushima, Japan
Site not named
Kumamoto, Japan
Site not named
Kyoto, Japan
Site not named
Kyoto, Japan
Site not named
Nagasaki, Japan
Site not named
Okayama, Japan
Site not named
Osaka, Japan
Site not named
Tokushima, Japan
Site not named
Wakayama, Japan
Site not named
Nagoya, Aichi-ken, Japan
Site not named
Urayasu, Chiba, Japan
Site not named
Ōgaki, Gifu, Japan
Site not named
Maebashi, Gunma, Japan
Site not named
Asahikawa, Hokkaido, Japan
Site not named
Sapporo, Hokkaido, Japan
Site not named
Amagasaki, Hyōgo, Japan
Site not named
Kobe, Hyōgo, Japan
Site not named
Kita, Kagawa-ken, Japan
Site not named
Tsu, Mie-ken, Japan
Site not named
Kashihara, Nara, Japan
Site not named
Hirakata, Osaka, Japan
Site not named
Suita, Osaka, Japan
Site not named
Ōtsu, Shiga, Japan
Showing 40 of 62 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.